VSV-IFNbeta-NIS
AXP000119.2 · Oncolytic virus
- Platform
- vesicular stomatitis virus (Indiana serotype, recombinant)
- Originator
- Mayo Clinic
- Sponsor
- Vyriad
Names
| Name | Type | Source |
|---|---|---|
| VSV-IFNbeta-NIS | preferred name | curator |
| Voyager-V1 | brand | ncit |
| VSV-hIFNbeta-NIS | code | ncit |
| VSV-IFNb-NIS | synonym | ncit |
| VV1 ambiguous | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Rhabdoviridae
- Virus
- vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
- Strain
- Indiana, recombinant
- Replication
- replicating
- Modifications
- human IFN-beta and NIS cassettes inserted
- Transgenes
- IFNB1, SLC5A5
- Route
- intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C131580
Approvals
No regulatory approval recorded.
Clinical trials (7)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Recruiting | Phase 2 | 2026-04-21 | 2033-08-01 | 18 | Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8 |
| NCT06508463 | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | Recruiting | Phase 1 | 2024-01-05 | 2028-12-31 | 21 | Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Peripheral T Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Relapsed Anaplastic Large Cell Lymphoma; Relapsed Mycosis Fungoides; Relapsed Peripheral T-Cell Lymphoma |
| NCT04291105 | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Active not recruiting | Phase 2 | 2020-04-24 | 2026-10 | 87 | Colo-rectal Cancer; Head and Neck Squamous Cell Carcinoma; Melanoma |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | Active not recruiting | Phase 1/2 | 2019-04-09 | 2025-07-31 | 33 | Neuroendocrine Carcinoma; Non Small Cell Lung Cancer; Renal Cell Carcinoma (RCC); Solid Tumor |
| NCT03120624 | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer | Active not recruiting | Phase 1 | 2017-09-15 | 2023-08-29 | 34 | Metastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinosarcoma; Stage IV Uterine Corpus Cancer AJCC v7 |
| NCT03017820 | A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | Recruiting | Phase 1 | 2017-04-04 | 2028-12-31 | 99 | B-Cell Non-Hodgkin Lymphoma; Histiocytic and Dendritic Cell Neoplasm; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Plasma Cell Myeloma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Acute Myeloid Leukemia; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Plasma Cell Myeloma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Recruiting | Phase 2 | 2010-03-01 | 2030-12 | 5000 | Angiosarcoma; Breast Cancer; Breast Neoplasms; Breast Tumors; Early-stage Breast Cancer; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Hormone Receptor Negative Tumor; Hormone Receptor Positive Tumor; Locally Advanced Breast Cancer; TNBC - Triple-Negative Breast Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41879562 | Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer. | Radiology. Artificial intelligence | 2026 | cited by trial NCT01042379 |
| PMID 42130226 | Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer. | Journal of surgical oncology | 2026 | name in abstract: Voyager-V1 |
| PMID 42530945 | Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. | JAMA oncology | 2026 | cited by trial NCT01042379 |
| PMID 42545411 | Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial. | Annals of surgical oncology | 2026 | cited by trial NCT01042379 |
| PMID 42619946 | Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy. | medRxiv : the preprint server for health sciences | 2026 | cited by trial NCT01042379 |
| PMID 42811224 | Separating Ranking Signal, Incremental Feature Value, and Evaluation-Induced Optimism in Breast MRI Treatment-Effect Analysis: Foundation Model and Radiomic Representations. | Journal of imaging informatics in medicine | 2026 | cited by trial NCT01042379 |
| PMID 42911610 | Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer: The I-SPY2.2 Randomized Clinical Trial. | JAMA oncology | 2026 | cited by trial NCT01042379 |
| PMID 39158353 | Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer. | Journal of the American Medical Informatics Association : JAMIA | 2025 | cited by trial NCT01042379 |
| PMID 39625569 | Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. | Breast cancer research and treatment | 2025 | cited by trial NCT01042379 |
| PMID 40526879 | Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. | JCO precision oncology | 2025 | cited by trial NCT01042379 |
| PMID 40551254 | Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. | Breast cancer research : BCR | 2025 | cited by trial NCT01042379 |
| PMID 40639409 | A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images. | Physics in medicine and biology | 2025 | cited by trial NCT01042379 |
| PMID 40679371 | Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI. | Radiology. Imaging cancer | 2025 | cited by trial NCT01042379 |
| PMID 40777112 | Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial. | Frontiers in oncology | 2025 | cited by trial NCT01042379 |
| PMID 38180338 | Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge. | Radiology. Imaging cancer | 2024 | cited by trial NCT01042379 |
| PMID 38745646 | Circulating tumor DNA: from discovery to clinical application in breast cancer. | Frontiers in immunology | 2024 | cited by trial NCT01042379 |
| PMID 39277671 | Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. | Nature medicine | 2024 | cited by trial NCT01042379 |
| PMID 39277672 | Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. | Nature medicine | 2024 | cited by trial NCT01042379 |
| PMID 39613746 | Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. | Nature communications | 2024 | cited by trial NCT01042379 |
| PMID 36898933 | Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet? | Blood reviews | 2023 | cited by trial NCT03017820 |
| PMID 37029329 | Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial. | Breast cancer research and treatment | 2023 | cited by trial NCT01042379 |
| PMID 37325931 | Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial. | Annals of surgery | 2023 | cited by trial NCT01042379 |
| PMID 37505107 | Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment. | Radiology. Imaging cancer | 2023 | cited by trial NCT01042379 |
| PMID 38086377 | Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. | Cell reports. Medicine | 2023 | cited by trial NCT01042379 |
| PMID 35175355 | Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. | Blood advances | 2022 | cited by trial NCT03017820 |
| PMID 35623341 | Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. | Cancer cell | 2022 | cited by trial NCT01042379 |
| PMID 35993306 | Postneoadjuvant treatment for triple-negative breast cancer. | Current opinion in oncology | 2022 | cited by trial NCT01042379 |
| PMID 36069821 | Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial. | JAMA surgery | 2022 | cited by trial NCT01042379 |
| PMID 36456573 | Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. | NPJ breast cancer | 2022 | cited by trial NCT01042379 |
| PMID 34529000 | Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. | JAMA oncology | 2021 | cited by trial NCT01042379 |
| PMID 34741021 | RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. | Nature communications | 2021 | cited by trial NCT01042379 |
| PMID 32031889 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020 | cited by trial NCT01042379 |
| PMID 32053137 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. | JAMA oncology | 2020 | cited by trial NCT01042379 |
| PMID 32450725 | Atezolizumab in the treatment of metastatic triple-negative breast cancer. | Expert opinion on biological therapy | 2020 | cited by trial NCT01042379 |
| PMID 32701140 | Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. | JAMA oncology | 2020 | cited by trial NCT01042379 |
| PMID 28851423 | The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. | Breast cancer research : BCR | 2017 | cited by trial NCT01042379 |
| PMID 27406346 | Adaptive Randomization of Neratinib in Early Breast Cancer. | The New England journal of medicine | 2016 | cited by trial NCT01042379 |
| PMID 27406347 | Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. | The New England journal of medicine | 2016 | cited by trial NCT01042379 |
| PMID 21796368 | Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). | Breast cancer research and treatment | 2012 | cited by trial NCT01042379 |
| PMID 22198468 | Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). | Breast cancer research and treatment | 2012 | cited by trial NCT01042379 |
| PMID 22623692 | Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. | Radiology | 2012 | cited by trial NCT01042379 |
| PMID 22649152 | Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2012 | cited by trial NCT01042379 |
Notes
Recombinant VSV expressing human interferon beta and the sodium iodide symporter; brand/development name Voyager-V1 (VV1). Mayo Clinic and Vyriad both sponsor trials. The IFN-beta-only predecessor (NCT01628640) is a separate program, VSV-hIFNbeta. Transgenes moved from targets to virus.tsv (spec 0.2).
How to cite
VSV-IFNbeta-NIS (AXP000119.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000119.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.